None listed
Conditions
Brief summary
Hyperbaric oxygen is the provision of oxygen in a compression chamber.The aim of this trial is to test the hypothesis that hyperbaric oxygen treatment (HBOT) may improve symptoms in people with Long-COVID . We will compare symptoms of those allocated to the HBOT to participants allocated to no HBOT.
Interventions
The treatment is hyperbaric oxygen daily for 10 days (mon to Friday) for 90 mins at 2.4 ATA (atmospheres absolute). This is a commonly used treatment table known as a US Navy Table 14 ( USNTable 14). The period may be over more than two weeks if the participant has any intercurrent illness which prevents ear equalisation and requires deferment.
Oxygen is given in a multiplace chamber by TGA approved hoods or masks depending on participant preference and comfort of fit. They sit in an easy reclin
The treatment is hyperbaric oxygen daily for 10 days (mon to Friday) for 90 mins at 2.4 ATA (atmospheres absolute). This is a commonly used treatment table known as a US Navy Table 14 ( USNTable 14). The period may be over more than two weeks if the participant has any intercurrent illness which prevents ear equalisation and requires deferment. Oxygen is given in a multiplace chamber by TGA approved hoods or masks depending on participant preference and comfort of fit. They sit in an easy recliner for the duration of treatment. The treatment is given by certified Hyperbaric physicians in an accredited hyperbaric facility under the oversight of a Senior ANZCA accredited Hyperbaric Physician and Anaesthetist.
Sponsors
Wesley Hyperbaric
Study design
Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Blinded (masking used) (Investigator)
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
• 18 to 65-year old • COVID-19 at least 12 weeks prior, +PCR test/ RAT and/or documented clinical symptoms • Active lifestyle before contracting COVID-19
Exclusion criteria
• Pregnant or lactating women • Individuals that are unable walk or get in and out of bed by themselves unaided • Inability to provide written informed consent • Inability or unwillingness to adhere to 10 HBOT treatment sessions over a 2 to 3 week- time period or to complete questionnaires/testing • Claustrophobia and inability to enter the hyperbaric chamber for session • Inability to effectively equalise the middle ear during ambient pressure changes. History of tympanic membrane perforation, head and neck surgery with compromised Eustachian tube function, including tracheostomy, mastoidectomy, middle ear surgical procedures and cochlear implants • Contraindication to HBOT such as cardiac or respiratory contraindication, bleomycin, spherocytosis or pulmonary fibrosis • Involved in another clinical trial that does not allow enrolment in other clinical trials
Outcome results
None listed